Leukemia in focus: expert talks on cell therapy

Logo

Leukemia in focus: expert talks on cell therapy

Cellular therapies have delivered significant breakthroughs in the treatment of leukemia, offering potent, targeted options for patients. This collection of expert talks explores the cutting-edge science and clinical developments that continually advance the fight against this disease.

The long journey of CAR T cells: from hematology to oncology and autoimmune disorders

Prof. Franco Locatelli, MD, from the IRCCS Ospedale Pediatrico Bambino Gesù in Rome, Italy, discusses the journey and evolution of CAR T cells in therapeutic use, from treating hematological and oncological conditions to their more recent applications in autoimmune disorders.

Prof. Franco Locatelli, MD @ MACS Cell and Gene Therapy Days 2025

Prof. Franco Locatelli, Head of the Department of Paediatric Haematology and Oncology and Cell and Gene Therapy, Bambino Gesù Children’s Hospital, Rome, Italy

Prof. Franco Locatelli, MD

Head of Pediatric Hematology and Oncology and Cell and Gene Therapy at Bambino Gesù Children's Hospital, Rome, Italy

Franco Locatelli is Full Professor of Pediatrics at the Catholic University of the Sacred Heart in Rome and Head of the Department of Paediatric Haematology and Oncology and Cell and Gene Therapy at the Bambino Gesù Children’s Hospital in Rome. Prof. Locatelli was President of the Italian Association for Pediatric Haematology/Oncology (AIEOP) from 2004 to 2006 and he served as Chair of the European EWOG-MDS consortium from 2005 to 2011. Prof. Locatelli leads the largest allogeneic hematopoietic stem cell transplantation program in Italy.

He is an expert in pediatric hematological malignant and non-malignant disorders. Prof. Locatelli currently serves as chairperson of the current diagnostic and treatment protocol for children with newly diagnosed acute myeloid leukemia and is the Italian coordinator of the consortium on relapsed acute lymphoblastic leukemia. In addition, Prof. Locatelli is chairperson of the international protocol of chemotherapy-free treatment of childhood acute promyelocytic leukemia, the coordinator of AIEOP’s Acute Non-Lymphoblastic Leukemia Working Group and is the principal investigator of the forthcoming academic global study on conditioning hematopoietic stem cell transplantation in acute lymphoblastic leukemia in children.

During his career, Prof. Locatelli has provided relevant contributions to the study of childhood leukemia, myelodysplastic syndromes, thalassemia, innate immunity, immune reconstitution after transplantation, tumor immunology, induction of tolerance towards alloantigens and anti-viral cellular immunity. His current main research interests are CAR T cells for both B-cell malignancies, brain neoplasia and solid tumors (neuroblastoma), and gene therapy/genome editing for hemoglobinopathies.

Prof. Locatelli is the author or co-author of 1419 peer-reviewed articles published in international journals (including New England Journal of Medicine, JAMA, Nature, Nature Genetics, Nature Communications, The Lancet, Lancet Haematology, Lancet Oncology, Lancet Respiratory Medicine, Journal of Clinical Oncology, Journal of Experimental Medicine, Blood, Cancer Research, Leukemia, etc.). With 69,840 citations, he has an H-index of 125 (Scopus source). Since February 2019, Prof. Locatelli is serving as President of the National Council of Health (Consiglio Superiore di Sanità). In December 2021, Prof. Locatelli was nominated 1st Class/Knight Grand Cross (Cavaliere di Gran Croce) by the President of the Italian Republic. Prof. Locatelli was awarded an Honoris Causa Degree in Medicine Biotechnology, by the University of Modena and Reggio Emilia, in March 2025.

Rapid succession of graft engineering and CAR T therapies facilitated by PoC manufacturing

Allogeneic hematopoietic cell transplantations and CAR T cells are being increasingly used for the treatment of neoplastic and immune disorders. Despite remarkable progress, substantial unmet medical needs remain, including accessibility, adverse events, cost, and disease recurrence. In this lecture, Prof Leung will discuss his experience in solving these problems in the USA and in Asia by rapid successions of graft engineering and CAR T therapies facilitated by point-of-care manufacturing.

Prof. Wing Leung @ MACS Cell and Gene Therapy Days 2025

Prof. Wing Leung, Director of the Children's Blood and Cancer Centre, KK Women's and Children's Hospital, Singapore and Prof. at Duke-NUS Medical School, Singapore

Prof. Wing Leung

Director of the Children's Blood and Cancer Centre, KK Women's and Children's Hospital, Singapore and Professor at Duke-NUS Medical School, Singapore

Professor Wing Leung is the Director of the Children's Blood and Cancer Centre at KK Women's and Children's Hospital, Singapore. He is a Professor at Duke-NUS Medical School. Previously, Professor Leung was a faculty member at Johns Hopkins University, and he held the position of Chair of Bone Marrow Transplantation and Cellular Therapy at St. Jude Children's Research Hospital. He also served as the Chair of the Department of Paediatrics at the University of Hong Kong.

Outcomes of low-cost, point-of-care manufactured CAR T cell therapy for B cell acute leukemia and non-hogkin lymphoblastic lymphoma in Vietnam

Purpose: This study aims to analyze the safety and primary efficacy of point-of-care CD19 CAR T cell therapy produced locally at low cost for the treatment of CD19+ B cell acute lymphoblastic leukemia (ALL) and non-Hodgkin lymphoma (NHL) in Vietnam.

Methods: A phase 1 clinical trial was conducted from August 2023 to March 2025. CD19 CAR T cells for 8 ALL patients and 8 NHL patients were manufactured using the automated CliniMACS Prodigy® System. CAR T cells were infused with doses ranging from 0.54 to 2.17×106 cells/kg.

Results: The number and percentage of CAR T cells at harvest were comparable between the 12-day and 8-day culture groups; however, viability was significantly better in the latter group (p=0.01). Upon treatment, the most common side effects included cytokine release syndrome (13 patients) and neurological toxicity (2 patients). No mortality related to CAR T therapy was observed. All ALL patients achieved complete remission after CAR T cell infusion on day 30. At 6 months, 5 patients (62.5%) remained in complete remission. 7 out of 8 NHL patients achieved complete remission on day 90, and 6 remained in complete remission at 6 months. One patient is awaiting assessment.

The total cost of CAR T cell therapy was approximately $140,000 per patient, with around $80,000 allocated to the CAR T product and $60,000 for treatment costs.

Conclusion: CD19 CAR T products can be produced at low cost. CAR T treatment is relatively safe and offers a promising therapeutic option for refractory/relapsed CD19+ NHL and ALL in a developing country like Vietnam.

Low-cost CD19 CAR T can be produced for refractory/relapsed CD19+ NHL and ALL.

Nguyen Thanh Liem, MD @ MACS Cell and Gene Therapy Days 2025

Nguyen Thanh Liem, MD, Vinmec Research Institute of Stem cell and Gene Technology, Hanoi, Vietnam

Prof. Nguyen Thanh Liem, MD

Director of the Vinmec Research Institute of Stem Cell and Gene Technology, Hanoi, Vietnam

Prof. Nguyen Thanh Liem is a pioneer and innovator in pediatric endoscopic surgery and stem cell transplantation. He graduated from Hanoi Medical University in 1976 and completed medical residency program in Surgery at Viet Duc Hospital in 1979. He defended his PhD thesis in 1991 and was appointed as a Medical Professor in Surgery in 2009.

He is an internationally recognized inventor for his seven advanced operative techniques in pediatric surgery. Regarding stem cell studies, Prof. Liem is a pioneer of using stem cell therapy for unmet diseases in children such as cerebral palsy due to oxygen deprivation, due to neonatal icterus, due to intracranial hemorrhage, neurological sequelae after near death drowning, autism, bronchopulmonary dysplasia, and liver cirrhosis due to biliary atresia. Throughout his career, he has been in charge of a number of important positions such as Director of Vietnam National Children Hospital from 2002 to 2012; Director of Vinmec International Hospital from 2013-2016; Vice President of Asian Association of Pediatric Surgery; President of Vietnam Association of Pediatric Surgery. Currently, Prof. Liem is the director of Vinmec Research Institute of Stem Cell and Gene Technology.

He has published 135 studies on the international journals and over 200 papers on domestic journals. He is the editor and author of six chapters of the book titled, “Cell Therapy: Stem Cells and Regenerative Medicine”, which is shortly published by Springer Nature in 2025. He is also the co-author of surgery pediatrics textbooks published in the UK and the US, such as Operative Pediatric Surgery, Ashcraft’s Pediatric Surgery, and Pediatric Laparoscopic and Thoracoscopic Surgery.

Prof. Nguyen Thanh Liem has been invited to give lectures and performed demonstrative surgeries in many countries including the US, France, Netherlands, Italia, Australia, Japan, India, South Korea, and more.

By his dedicated and delightful contributions to the medical practices and research, he has been honored many prestige awards conferred by the Vietnam government like the Ho Chi Minh Award, National Labor Hero Medal and Award of Vietnam Talent.

In 2018, he has been awarded the 2018 Nikkei Asia Prize in the Science and Technology category thanks to his contribution to develop and popularize pediatric endoscopic surgery in Asia and the world. He is categorized in the top 100 scientists in Asia by the Singapore Journal in 2019.

CD45RA+ TN depletion of PBSC grafts for prevention of chronic GVHD – results from clinical trials and laboratory studies

Allogeneic hematopoietic stem cell transplantation (HCT) represents the best available consolidation therapy for most types of high-risk or relapsed leukemia and is curative for many patients. However, current approaches to HCT are frequently complicated by leukemic relapse and, or, by the development of severe or chronic graft-versus-host disease (GVHD). GVHD involves an immune-mediated attack on host tissues involving donor T cells, other immune cells and cytokines and results in a frequently debilitating, sometimes life-threatening, multi-system illness.

Furthermore, the development of GVHD generally necessitates treatment with pharmacological immunosuppression, which may preclude the effective implementation of adoptive T cell immunotherapy to prevent and treat relapse of leukemia. Complete depletion of T cells (TCD) from hematopoietic stem cell grafts is effective in preventing GVHD in animals and humans. However, recipients of TCD HCT are vulnerable to opportunistic infections and related complications.

Newer HCT strategies that involve selective depletion of T cells responsible for GVHD, whilst preserving T cells specific for opportunistic infections, may lead to improved HCT outcomes. In murine models of GVHD, the infusion of bone marrow with naive T (TN) cells or unseparated splenocytes leads to severe GVHD, whilst the infusion of bone marrow with effector or central memory T cells results in no GVHD, or milder GVHD, respectively. In in vitro experiments using human T cells we demonstrated that the naive CD8+ T cell population contains significantly more T cells that specifically respond to minor histocompatibility antigens, the molecular targets of alloreactive T cells in HLA-identical HCT. We performed three prospective single-arm clinical trials to evaluate whether selective depletion of naive T cells from allogeneic peripheral blood stem cell grafts (PBSC) can prevent or reduce GVHD whilst preserving protection against opportunistic pathogens. These single-arm trials included 138 acute leukemia patients aged 1–60 years old who received high-intensity or intermediate-intensity conditioning regimens followed by HLA-matched related or unrelated donor TN-depleted PBSC grafts with calcineurin-inhibitor–based GVHD prophylaxis. In these trials, a very low incidence of severe acute and any cGVHD, without apparent excess risks of relapse or non-relapse mortality, distinguishes this novel graft engineering strategy from other hematopoietic cell transplantation approaches (Bleakley et al JCO 2022). TN-depleted PBSC grafts are currently being compared to T-cell–replete grafts followed by post-transplantation cyclophosphamide (PTCy) in an ongoing randomized controlled trial. Longitudinal post-HCT samples of peripheral blood lymphocytes from subjects enrolled in these trials are being evaluated by spectral flow cytometry; preliminary data will be presented.

Marie Bleakley, MD, PhD, MMSc @ 51st EBMT Annual Meeting 2025

Marie Bleakley, B.M.B.S, PhD, MMSc, Professor of Pediatrics, University of Washington, Seattle, USA

Marie Bleakley, MD, PhD, MMSc

Fred Hutchinson Cancer Research Center, Seattle, USA

Marie Bleakley, MD, PhD, MMSc, received her medical degree, master’s degree, and PhD in Australia and completed post-graduate training in pediatric oncology and bone marrow
transplantation (BMT) in Australia and Fred Hutchinson Cancer Center (Fred Hutch)
in Seattle, USA.

She is currently a Professor of Pediatrics at the University of Washington and at Fred Hutch where she conducts translational research in the Translational Science and Therapeutics Division and attends on the pediatric BMT service. Dr. Bleakley’s major research interests include the development of new immunotherapies and transplant strategies to prevent leukemic relapse and graft-versus-host disease following allogeneic hematopoietic stem cell transplantation (HCT).

Obe-cel cell therapy manufacturing process development

The FELIX study was the latest stage of the development of obecabtagene autoleucel (obe-cel) for patients with relapsed/refractory (r/r) Adult B Cell Acute Lymphoblastic Leukemia (ALL) at the UK-based CAR T cell therapy company, Autolus Therapeutics. The approval of its Biologics License Application (BLA) by the U.S. Food and Drug Administration (FDA) is expected by November 2024, and Autolus seeks for its first autologous CAR T product to become commercial. The journey for obe-cel started at the University College London Hospitals and UCL, in collaboration with Autolus under the oversight of Claire Roddie (Trial Investigator) and Martin Pule (Founder and CSO of Autolus).

The obe-cel manufacturing process evolved from highly manual manipulations and expansion in a rocking motion bioreactor to the current semi-automated CliniMACS Prodigy®-based cell processing. While the process development had a challenging journey due to the high impact of the disease burden on the quality of the patient starting material, Autolus was able to conclude the trial with a robust process, which serves as a foundation for its future platform processes. Moreover, Autolus established a short vein-to-certification (V2C) time (median of 21 days), which is being improved.

Obe-cel shows a very good safety and efficacy profile and has the potential to be a great option for patients with B-ALL.

Kostadinka Lilova, PhD @ Miltenyi Biotec Cell and Gene Therapy Days 2024

Kostadinka Lilova, PhD, Executive Director, Cell Process Development, Product Delivery, Autolus Therapeutics, UK

Kostadinka Lilova, PhD

Executive Director, Cell Process Development, Product Delivery, Autolus Therapeutics, UK

Koki Lilova, PhD, is Executive Director for Cell Process Development at Autolus. Her education was completed in two different parts of the world, Bulgaria and Canada, where she earned her degrees in chemical and biochemical engineering, respectively. She has been working in the cell therapy process development area since 2007. For the past six years, her focus has been on immuno-oncology process development for NK-allogeneic and T cell autologous products at Janssen Pharmaceuticals and Autolus. Koki has been with Autolus since 2021.

Advancing CAR T cell therapy in AML

Hear from Marion Subklewe at the Miltenyi Cell and Gene Therapy Summit 2024 as she speaks on advancing CAR T cell therapy in AML.

Prof. Dr. med. Marion Subklewe @ Miltenyi Biotec Cell and Gene Therapy Days 2024

arion Subklewe, MD, Head of Cellular Immunotherapy, Department of Hematology & Oncology, LMU - University Hospital of Munich, Germany

Prof. Dr. med. Marion Subklewe

Head of Cellular Immunotherapy, Department of Hematology & Oncology, LMU - University Hospital of Munich, Germany

Marion Subklewe is Professor of Internal Medicine with a focus on cellular immunotherapy within the medical department for hematology/oncology at the LMU – University Hospital Munich. She is Head of the immunotherapy program in hematology and the CAR T program at the University Hospital Munich, leading an intermediate care unit and an early clinical trial unit, as well as a large outpatient clinic for those with acute leukemias and aggressive lymphomas.

She is heading the lab for Translational Cancer Immunotherapy at the Gene Center Munich with a focus on translational research in T cell-based immunotherapy. Her research is focused on understanding the mode of action and resistance of bispecific and bifunctional antibody constructs. Current research integrates an adapter CAR T cell platform and combinatorial approaches in the setting of AML. She is Speaker of the national “Harmonize MRD Flow” consortium and a member of the ELN working group on MRD. She is the Principal Investigator in I-IT trials in AML and ALL as well as in over 30 oligo- and multi-centric C-IT trials in leukemias and lymphoma.

AdaptNK - A novel allogeneic adaptive NK cell therapy product

Since the discovery of adaptive natural killer (NK) cells, intensive research has been performed by our group and others, trying to harness their powerful cytotoxic capabilities for clinical use. We have developed a method for selectively expanding these single-KIR expressing cells to large numbers, enabling them to be used in vivo in a missing-self setting.

The GMP-compliant AdaptNK off-the-shelf platform utilizes an 11-day expansion of adaptive NK cells from select third-party “super donors” with pre-existing adaptive subsets. On average, the AdaptNK product expands 470-fold, featuring maximal alloreactivity via expression of a single self-HLA-specific KIR and HLA-E checkpoint evasion through NKG2C expression without NKG2A.

Moreover, the AdaptNK product displays potent ADCC capacity due to high CD16 expression, enabling antibody/engager combinations, and alloreactivity against primary leukemic blasts from AML patients. NK cells has shown great promise as a source for allogeneic cell therapy against hematological myeloid malignancies in our previous study (and others). We are now planning a clinical phase I/II study with AdaptNK in a KIR-ligand mismatched setting against chemotherapy-refractory acute myeloid leukemia and myelodysplastic syndrome. The talk describes our previous NK cell therapy trial, at Karolinska University Hospital, the developmental steps of the new AdaptNK-product, and the coming trial showing where allogeneic NK cell therapy fit in today’s cell therapy landscape.

Andreas Björklund, MD, PhD @ Miltenyi Biotec Cell and Gene Therapy Days 2023

Andreas Björklund, MD, PhD

Unit for Cell Therapy and Allogeneic Stem Cell Transplantation, Karolinska Institute, Sweden

Andreas Björklund, MD, PhD, works at CAST, the unit for cell therapy and allogeneic stem cell transplantation, at Karolinska University Hospital. He received his medical degree at Uppsala University (1999) and became interested in hematology and the immunology related to allogeneic hematopoietic stem cell transplantation (SCT).

In parallel with specialty training in hematology and internal medicine at the Karolinska, he dedicated his PhD work to study SCT-immune reconstitution during CMV-infection, and the impact on the NK cell repertoire leading to so-called adaptive NK cell expansions. As a post doc in KJ Malmberg at Karolinska he acted as the PI for the first Swedish adoptive NK cell therapy trial against MDS and AML (2012-2018). He is currently involved in developing the groups next NK trial that builds on cryo-preserved, expanded, single-KIR-expressing, adaptive NK cells from CMV seropositive “Superdonors”, that will be used off-the-shelf in a phase I/II-trial in KIR-ligand mismatched patients against relapsed/ refractory AML and MDS.

Manufacturing of NK cells for the clinic: the Spanish experience

I will present a standardized method to manufacture a high number of clinical-grade NK cells, ideal for infusing into patients. Then, further expand on the optimization of protocols and a glimpse into clinical data results of infused NK cells. Listen in to learn how to design your cell manufacturing, how to ensure compliance and quality in your cell product, and how the starting material impacts the final product.

Webinar given by Dr. Antonio Perez-Martinez, MD, PhD

Dr. Antonio Perez-Martinez, MD, PhD

Head of Pediatric Hemato-Oncology and Hematopoietic Transplant Service, La Paz University Hospital, Spain

Dr. Antonio Perez-Martinez, MD, PhD, is a medical specialist in pediatrics and Head of Pediatric Hematology and Oncology Service at the University Hospital La Paz, Madrid, Spain. He is also Pediatric Department Head at the Autonomous University of Madrid and Principle Investigator at the Foundation for Biomedical Research, Hospital La Paz, and has experience in over 20 active research projects as a principal investigator.

Current status and challenges of cell and gene therapies in India

The Department of Hematology at Christian Medical College, Vellore, India, has had an active hematopoietic cell transplant (HCT) program since 1986, performing 300+ HCT a year, of which around 250 allogeneic HCT, including haplo-identical HCT with graft manipulation in the pre- and post-PTCy era, and with CD34 selection transplants in the earlier era. There is an increased interest in graft manipulation for HCT, as well as using cell therapy alone as an adjunct to HCT to treat or reduce the risk of relapse in hematological malignancies.

An NK cell program with a phase II study in relapsed refractory acute myeloid leukemia (AML) has just been completed. The preliminary data, in addition to establishing safety, provides a signal to suggest efficacy, and we are keen to move this strategy to high-risk first remission AML HCT.

As viral reactivation is a major challenge in our current haplo-identical HCT program, we initiated a study using anti-cytomegalovirus (CMV)–directed CTL therapy or CD45RA+-depleted donor lymphocyte infusion (DLI) post haplo-identical HCT.

We have also made early steps into establishing a CAR T cell program in collaboration with Miltenyi Biotec. We hope to expand this program to other centers in the country with a decentralized manufacturing approach and to move into gene therapy for inherited hematopoietic disorders such as thalassemia major and sickle cell disease. In this presentation, I give an overview of the status and opportunities of cell and gene therapy in India and illustrate the regulatory pathways that we have followed and challenges that we face.

Vikram Mathews, MBBS, MD, DM @ Miltenyi Biotec Cell and Gene Therapy Days 2023

Vikram Mathews, MBBS, MD, DM

Head of Department of Hematology, Christian Medical College Vellore, India

Having completed his medical school training at Christian Medical College in 1991, Dr. Vikram Mathews, MBBS, MD, DM, spent two years in primary care hospitals, which included a rural hospital where he was one of two physicians. He subsequently completed his post-graduation in general medicine at the same institution where he had done his undergraduate training, followed by a sub-specialty training in clinical hematology, which he completed in 2001.

Dr. Mathews looked for opportunities to develop his basic science research skills further, obtaining a postdoctoral fellowship at the Stem Cell and Leukemia Unit at Washington University, St. Louis, MO, USA. In his third year at Washington University, he did a clinical bone marrow transplant fellowship. Dr. Mathews returned to India in 2004 and rejoined the Department of Hematology at Christian Medical College, where he is currently Professor of Clinical Hematology and Director of the institution.

CAR T manufacturing in an academic institution

At the Hospital Clinic of Barcelona, we have developed a second-generation CAR T (with 4-1BB as a co-stimulatory motif) targeting CD19 (ARI0001 or varnimcabtagene autoleucel), which is fully publicly funded and has received authorization for use under the hospital exemption regulation. It is the first academic and European CAR T approved worldwide for acute lymphoblastic leukemia B and is currently undergoing evaluation under the Priority Medicines (PRIME) designation by the European Medicines Agency (EMA), trying to obtain centralized marketing authorization.

Alongside ARI0001, we are also close to obtaining "hospital exemption" for ARI0002h (cesnicabtagene autoleucel), an anti-BCMA CAR T for multiple myeloma. Obviously, all these academic products meet the same quality requirements as commercial products and must also demonstrate effectiveness within the ranges of commercial products in clinical trials for approval.

Possibly, with these Barcelona products, we are paving the way to enable academic production to provide treatment options in cases where pharmaceutical companies are not interested in developing these products (such as rare diseases like pediatric tumors or even autoimmune diseases to low frequent autoantigens). Beyond cancer, other immune-mediated diseases (such as autoimmune disorders and systemic lupus erythematosus) are probably the next challenges for CAR T immunotherapies.

Martha Español Rego, PhD @ Miltenyi Biotec Cell and Gene Therapy Days 2023

Marta Español Rego, PhD

Manufacturing and monitoring of CAR T cell therapies, Hospital Clinic Barcelona, Spain

Marta Español Rego, PhD, works in the immunotherapy section of the Hospital Clinic of Barcelona (HCB). She finished her pharmacy residence in Immunology (FIR) in 2018 at HCB and obtained her PhD in 2023 at the University of Barcelona in the field of dendritic cell immunotherapy in colorectal cancer.

She has completed her immunology studies with a research stay at University Hospital La Paz (Madrid) and at the Center for Cancer Immune Therapy (Denmark), focusing in immunodeficiency diagnosis, molecular biology techniques, and adoptive cell therapy with tumor-infiltrating lymphocytes. She started to work as an immunology specialist at HCB in 2018 and also participates as a professor at University of Barcelona in the Master in Translational Medicine and the Master of Biomedicine. During all this time, Marta has gained experience in transplant immunology, clinical immunology, and immunotherapy. She is mainly involved in the development of anti-tumor immunotherapy as the responsible lead in manufacturing and monitoring of CAR T cell therapy. She is also involved in regulatory aspects of the treatments produced in the Advanced Therapies Unit of the HCB.

You have previously chosen International as your location.
What do you want to do?